SECURITIES AND EXCHANGE COMMISSION
                                                   WASHINGTON, DC   20549

                                               FORM 10-KSB

[ x ]    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934

                               For the fiscal year ended: October 31, 1995


                                                    OR

[   ]    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934

For the transition period from            to

Commission file number:                 No. 2-86360

                                            INFORMEDICS, INC.
                              (Name of small business issuer in its charter)

         Oregon                                93-0750571
(State of incorporation)         (I.R.S. Employer Identification No.)

                                 4000 Kruse Way Place, Bldg 3, Suite 210,
                                 Lake Oswego, OR  97035
                                 (Address of principal executive offices)

                                Issuer's telephone number: (503) 697-3000

         Securities registered pursuant to Section 12(b) of the Act: 
                   None

         Securities registered pursuant to Section 12(g) of the Act:
                   Common Stock, $.01 Par Value

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or
for such shorter  period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes X
No

Check if there is no disclosure of delinquent  filers in response to Item 405 of
Regulation  S-B contained in this Form,  and no disclosure  will be contained to
the best of issuer's  knowledge in definitive  proxy or  information  statements
incorporated  by reference  in Part III of this Form 10-KSB or any  amendment to
this Form 10-KSB [   ]

State the issuer's revenues for its most recent fiscal year:  $5,151,547

State the  aggregate  market  value of the voting  stock held by  non-affiliates
computed by reference  to the price at which the stock was sold,  or the average
bid and asked prices of such stock, as of December 29, 1995:  $3,520,634,  based
on the average bid and asked prices.

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest  practicable date:  2,643,622 shares of $0.01 par value
common stock at December 29, 1995.



                                   DOCUMENTS INCORPORATED BY REFERENCE

Parts of the  issuer's  Annual  Report to  Shareholders  for the year ended
October 31, 1995 are incorporated by reference into Parts I, II and III of this
Report.  Parts of the issuer's  definitive  Proxy  Statement for the 1996 annual
meeting  of  shareholders  to be held on  March  15,  1996 are  incorporated  by
reference into Part III of this Report.


Transitional Small Business Disclosure Format   (Check One):
     Yes           No  X

<PAGE>

                                                  TABLE OF CONTENTS



Part I

(Portions of Item 1 and Item 2 are  incorporated  herein by  reference  from the
Company's 1995 Annual Report to Shareholders)

Item 1     Business ..............................................3
Item 2.    Properties ............................................6
Item 3.    Legal Proceedings .....................................6
Item 4.    Submission of Matters to a Vote of Security Holders ...6


Part II

(Item 5, Item 6 and Item 7 are incorporated herein by reference from
the Company's 1995 Annual Report to Shareholders)

Item 8.     Changes in and Disagreements with Accountants on
            Accounting and Financial Disclosure ..................7


Part III

Items 9, 10 and 11 are  incorporated  herein  by  reference  from the  Company's
definitive Proxy Statement for its 1996 annual meeting of shareholders.)

Item 12.     Certain Relationships and Related Transactions.......8


Part IV

Item 13.     Exhibits and Reports on Form 8-K ....................9

Signatures.......................................................11










Informedics, ClinicManager, LifeLine and StarPath are trademarks of
Informedics, Inc.

<PAGE>


                                                       PART I

Parts of Items 1 and 2 are  incorporated  herein by reference from the Company's
1995 Annual Report to Shareholders,  as indicated below. Except for the portions
of the  Annual  Report  to  Shareholders  that are  incorporated  into this Form
10-KSB, the Annual Report is not to be deemed filed as part of this Form 10-KSB.

ITEM 1 - BUSINESS

GENERAL

Informedics, Inc., formerly Western Star, Inc. (the "Company"), was organized
 under the laws of the State of Oregon on December 21, 1979.

The  Company  develops  and  markets a line of  computer  software  applications
designed  for use in the health  care  field.  The  computer  systems  typically
consist of computers,  peripheral  hardware  (such as disk drives and printers),
local area network (LAN)  hardware and software,  and the Company's  proprietary
software applications.

From 1986 until 1989, the Company  focused all of its  development and marketing
efforts  on a line  of  proprietary  blood  bank  data  management  systems.  In
September  1989,  the Company  purchased  a line of  pathology  data  management
systems.  The blood bank and pathology data management systems are compatible in
a number of ways.  Both  systems are  marketable  through the same  distribution
channels  to  health  care  providers,  both are  written  in the same  computer
programming language, and both operate on the same type of computer systems.

In October 1993, the Company  purchased a physician  practice  management system
and a laboratory  test request and  reporting  system.  The  physician  practice
management system is currently marketed in the Pacific Northwest. The laboratory
test request and reporting system is licensed exclusively to Corning Clinical
Laboratories, Inc., a major independent reference laboratory company.

In the fourth quarter of 1995, the Company  completed the  development and pilot
phase of the  application  software for the Oregon  Medical  Electronic  Network
(OMEN)  project,  which is being offered only by the Oregon Medical  Association
(OMA). The OMEN project is being marketed by the OMA for participation by Oregon
physicians,  laboratories,  pharmacies, insurance carriers and other health care
providers within the State of Oregon.

In addition to the sales of the Company's  numerous  product lines,  the Company
performs  ongoing  support  and  maintenance  and  programming  service  for its
customers.  After the  initial  installation  of a system and  related  customer
training,  the Company  provides  software  support,  furnishes  customers  with
upgrades of software and  hardware and  maintains  hardware  for  customers  who
purchase such services.

The computer hardware marketed by the Company are IBM-compatible  micro-computer
products,  running on either  Windows,  MS-DOS or UNIX  operating  systems.  The
Company has been a dealer for  numerous  hardware  manufacturers  and  presently
focuses  its  hardware  marketing  efforts on products  manufactured  by Compaq,
Novell,  Inc.,  Precision  Computer  Systems,  Inc.,  Hewlett  Packard and Epson
Pacific.

DESCRIPTION OF THE COMPANY'S PRODUCTS

The  Company's  application  software  for  OMEN  is  designed  to  improve  the
operational efficiency of physician offices by providing the electronic means to
determine the patient's health plan eligibility and coverage,  to seek treatment
authorizations  from primary care  physicians and health plans and to generate a
referral for services between the primary care and specialist physicians.

The Company's physician practice  management system,  called  ClinicManager,  is
designed to support  physician office  functions,  increase staff efficiency and
provide detailed  clinical  information.  ClinicManager  can meet the needs of a
wide range of clinics,  from a sole  practitioner  with one  office,  to a large
multi-specialty  clinic with several physician offices. The system provides full
functionality  in  accounts  receivable,   billing  and  insurance   processing,
electronic billing,  insurance  reimbursement and analysis,  patient scheduling,
resource management and accounts payable.

The blood bank data management systems,  called LifeLine, are modular, yet fully
integrated,  software systems which have been designed for the modern blood bank
and hospital transfusion service to monitor donor records,  unit inventory,  and
patient test and transfusion  history.  There are three primary  applications of
the LifeLine system.  The first application  supports the needs of the community
blood bank whose activities include drawing and managing blood donors as well as
testing,  processing and  distributing  blood products.  The second  application
meets the needs of a hospital  transfusion  service  which does not,  as a rule,
draw blood from donors. The third application  provides the features required by
a hospital  which draws blood from donors,  manages blood product  inventory and
maintains related patient test and transfusion information.

The pathology data management systems,  called StarPath,  are modular, yet fully
integrated,  software  systems that are  designed to fully  automate a pathology
department.  Each application  allows the pathology group to have direct control
over the content and  arrangement of work lists,  labels and reports.  There are
two primary applications of the StarPath system. The first application automates
the record keeping functions of a pathology  department in the areas of surgical
pathology,  cytology and  autopsies.  The second  application  is similar to the
first application except that it also includes the area of histology.

The laboratory test request and reporting  system,  developed by the Company for
Corning  Clinical  Laboratories,  Inc., is designed to automate the ordering and
reporting  of lab  tests  from a  physician's  office  or  medical  clinic to an
independent  reference  laboratory.  The system  provides  improved  accuracy of
patient  demographics,  insurance  information  and lab test requests,  improved
efficiency and speed in ordering lab tests,  and more timely receipt of lab test
results.

DISTRIBUTION OF PRODUCTS

The  Company's  revenue in fiscal 1995  included  sales from all product  lines:
OMEN, ClinicManager,  LifeLine,  StarPath and the Lab Test Request System. Sales
in fiscal 1995 included both direct sales to physician offices, medical clinics,
hospitals,  medical  laboratories  and blood  bank donor  centers,  and sales of
software to companies which agree to act as resellers of the Company's  systems.
The Company considers its operations to be in a single industry segment.

In fiscal 1995, the Company  recognized  revenue from two major customers,  HBO
and Company and Corning Clinical Laboratories,  Inc. representing 20% and 10% of
the  Company's  revenue,  respectively.  While  the  loss of  either  of  these
customers  might  initially  have a  material  adverse  impact on the  Company's
operating  results,  management  believes  that the effect of such loss would be
short term, as the Company would  concentrate  its marketing  resources on other
resellers and on direct sales.

COMPETITION

The  competition  for the  ClinicManager  system are companies that have similar
software  packages that run on mini- and  micro-computers.  Currently  there are
more companies  offering  products that compete with the  ClinicManager  product
than with any of the Company's other products.

The competition for LifeLine systems includes companies that market a blood bank
system as part of a complete  laboratory  information  system and companies that
offer a blood bank system as a stand-alone module.

The  competition  for the  StarPath  system  includes  companies  that  market a
pathology  system  as part  of a  complete  laboratory  information  system  and
companies that offer pathology as a stand-alone module.

One of the ways the  Company  has tried to  minimize  the  impact  of  competing
products in the  marketplace is by licensing the Company's  software  systems to
providers of hospital  laboratory  information  systems to enable them to market
the  Company's  systems,  instead  of  developing  their own blood  bank  and/or
pathology systems.  The Company has agreements with qualified  resellers who use
the Company's  systems to supplement their existing lines of medical  laboratory
software.  Total revenue recognized from these agreements was $1,144,131 in 1995
and $1,193,024 in 1994.

The Company  believes its products  have a competitive  edge in the  marketplace
based on price, product sophistication, design, flexibility, and reliability. In
addition,  with respect to the LifeLine system,  the governmental  regulation of
blood bank computerized  systems places a significant  barrier to entry for this
product.

BACKLOG

At October 31,  1995 and 1994,  the backlog of system  orders was  $347,878  and
$283,180,  respectively.  These amounts  represent the unrecognized  revenue for
customer  work in  progress,  and  undelivered  hardware and software as of such
dates.

Unexpired  maintenance  service  contracts  at  October  31,  1995 and 1994 were
$980,591 and $1,039,325, respectively.

PROTECTION OF PROPRIETARY SOFTWARE

Under  existing law, most computer  software  cannot be patented,  and copyright
laws provide only limited protection.  To protect its proprietary products,  the
Company  relies upon  copyright  and trade secret laws,  internal  nondisclosure
safeguards,  and restrictions on disclosure and transferability  incorporated in
its software license agreements.  However, as with all software,  it is possible
for users and competitors to wrongfully copy the Company's products. The Company
believes that, because of the rapid pace of technological change in the computer
industry,  patent,  copyright and  contractual  protection is of less  practical
significance  than other  factors,  such as the knowledge and  experience of the
Company's  management  and  personnel  and their  ability to  acquire,  develop,
enhance and market new products.

REGULATORY COMPLIANCE

In 1994,  the Food and Drug  Administration  ("FDA")  notified all developers of
blood bank software that such software is considered to be a medical device. The
FDA required each  developer to register as a medical  device  manufacturer  and
submit, by March 31, 1995, a pre-market notification (510K) report for its blood
bank  software.  The FDA  subsequently  extended  the  deadline  for  filing the
pre-market  notification  report to March 31, 1996. In fourth  quarter 1995, the
Company prepared and filed the required  pre-market  notification  (510K) report
with the FDA. At the time of the 1994 notice, the Company was already registered
as a medical device manufacturer.

In 1995,  the FDA  notified  the  Company  that prior  distributions  of certain
LifeLine software updates "meets the formal definition of a recall." The Company
expects to bring  closure to the recall in early 1996,  as it recently  released
LifeLine version 4.2, which addressed all outstanding  issues.  In 1995, the FDA
conducted  a  routine  inspection  of the  Company's  software  development  and
distribution  processes.  The  Company  has  responded  to  all  of  the  issues
identified  in the  inspection.  The FDA has not yet concluded its review of the
Company's  responses.  The  Company  believes  that  none of the  issues  raised
concerns health or safety but rather are focused on manufacturing  processes and
documentation.

SOFTWARE DEVELOPMENT COSTS

The Company  capitalized  certain  software  development  costs incurred  during
fiscal  1995 and 1994 in  accordance  with  Statement  of  Financial  Accounting
Standards  (SFAS) No. 86  "Accounting  for the Costs of Computer  Software to be
Sold,  Leased or  Otherwise  Marketed"  (see Note 1 to the  Company's  financial
statements,  which are incorporated  herein by reference from the Company's 1995
Annual Report,  Page 11). The Company is presently enhancing all of its software
product lines and, in accordance with SFAS No. 86, is capitalizing certain costs
associated with new releases. The Company incurred software development costs of
$1,377,906  in 1995 and $701,992 in 1994,  of which  $365,016 and $306,106  were
capitalized for 1995 and 1994, respectively.

EXPORT SALES

The  Company's  export sales for fiscal 1995 and 1994 were $93,814 and $216,445,
respectively.

EMPLOYEES

At December 29, 1995, the Company had 67 full-time employees.


ITEM 2 - PROPERTIES

The Company does not own any real property. The Company presently leases office,
production  and  warehouse  space  in  Lake  Oswego,   Oregon.   For  additional
information  about the Company's  leases,  see the 1995 Annual Report,  page 12,
"Lease Commitments," which is incorporated herein by reference.


ITEM 3 - LEGAL PROCEEDINGS

None.

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Not applicable.


<PAGE>


                                                       PART II

Except for Item 8, the information required by Part II is incorporated herein by
reference  from the Company's 1995 Annual Report to  Shareholders,  as indicated
below.


ITEM 5 - MARKET FOR COMMON STOCK AND RELATED SHAREHOLDER MATTERS

1995 Annual Report, page 4, "Common Stock and Related Shareholder Information."


ITEM 6 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
         RESULTS OF OPERATIONS

1995 Annual Report, pages  17 and 18, "Management's Discussion and Analysis
     of Financial Condition and Results of Operations."


ITEM 7 - FINANCIAL STATEMENTS

Financial Statements

1995 Annual Report, page 5, "Statements of Operations."

1995 Annual Report, pages 6 and 7, "Balance Sheets."

1995 Annual Report, page 8, "Statements of Cash Flows."

1995 Annual Report, page 9, "Statements of Cash Flows -
Supplemental Information."

1995 Annual Report, page 10, "Statements of Stockholders' Equity."

1995 Annual Report, pages 11 through 15, "Notes to Financial Statements."

1995 Annual Report, page 16, "Independent Auditors' Report."


ITEM 8 -  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE

None.
















<PAGE>




                                                     PART III


Information called for by Items 9, 10 and 11 is incorporated herein by reference
from the indicated sections of the Company's  definitive Proxy Statement for its
1996 annual meeting of shareholders.



                                                         The Company's
                                                        Proxy Statement
                                                         (Caption of
                                                     Applicable Section)
                                                     -------------------


ITEM  9 -DIRECTORS AND EXECUTIVE                "Election of Directors";
         OFFICERS, PROMOTERS AND CONTROL       "Executive Officers" and
         PERSONS; COMPLIANCE WITH SECTION       "Compliance With Section
         16(a) OF THE EXCHANGE ACT               16(a) of the Securities
                                                   Exchange Act"



ITEM 10 -EXECUTIVE COMPENSATION                 "Executive Compensation"

ITEM 11 -SECURITY OWNERSHIP OF CERTAIN          "Principal Shareholders"
         BENEFICIAL OWNERS AND MANAGEMENT

ITEM 12 -CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

None.


<PAGE>


                                                       PART IV

ITEM 13 - EXHIBITS AND REPORTS ON FORM 8-K

(a)   EXHIBITS

EXHIBIT           DESCRIPTION
3(a)              Restated Articles of Incorporation, as amended (1)

3(b)              Restated Bylaws, as amended (7)

4                 Form of Indemnification Agreement--
                  Directorship and Officership Agreement (2)

10(a)*            Restated 1983 Employees' Stock Option Plan (3)

10(b)*            Restated 1988 Employees' Stock Option Plan, as amended (4)

10(c)             Lease with Beim & James Properties, as amended (5)

10(d)*            Incentive Compensation Plan (5)

10(e)             Amendments to Lease with Kruse Way Holdings, Inc. (formerly
                  Beim & James Properties) (8)

11                Computation of Earnings Per Share

13                Portions of 1995 Annual Report to Shareholders, which are
                  incorporated by reference in this Form 10-KSB

20                Definitive Proxy Statement for 1996 Annual Shareholder
                  Meeting (6)

23                Independent Auditors' Consent

27                Financial Data Schedule

*  Management contract or compensatory plan or arrangement.

(1)  Incorporated herein by reference from the Company's annual report on Form
     10-K for the year ended October 31, 1993.

(2)  Incorporated herein by  reference  from the  Company's  definitive  proxy
     material  filed with the  Securities  and Exchange  Commission on April 28,
     1988.

(3)  Restated  1983  Employees'  stock  option  plan is  incorporated  herein by
     reference  from the  Company's  quarterly  report Form 10-Q for the quarter
     ended  April 30,  1988.  Amendment  to the Plan is  incorporated  herein by
     reference from the  registration  statement,  Form S-8 (Reg. No.  33-46474)
     filed with the Securities and Exchange Commission on March 19, 1992.

(4)  Incorporated  herein  by  reference  from the  Company's  definitive  proxy
     material filed with the  Securities and Exchange  Commission on February 8,
     1992.

(5)  Incorporated  herein by reference from the Company's  annual report on Form
     10-K for the year ended October 31, 1990.

(6)  To be filed with the  Securities  and Exchange  Commission  within 120 days
     after the end of the fiscal year covered by this Annual Report.

(7)  Incorporated  herein by reference  from the Company's  quarterly  report on
     Form 10-Q for the quarter ended April 30, 1993.

(8)  Incorporated  herein by reference from the Company's  annual report on Form
     10-KSB for the year ended October 31, 1994.


Upon written  request to the Chief  Financial  Officer,  Informedics,  Inc.,
4000 Kruse Way Place,  Bldg 3, Suite 210 Lake Oswego, Oregon 97035, the Company
will furnish shareholders  with a copy of any Exhibit  upon  payment of $.20 
per page, which represents the Company's reasonable expenses in furnishing the
Exhibit requested.

(b)  Reports  on Form 8-K - During the  quarter  ended  October  31,  1995,  the
     Company filed no reports on Form 8-K.

                                ********************************************


<PAGE>



                                                       SIGNATURES


Pursuant to the  requirements of section 13 or 15(d) of the Securities  Exchange
Act of 1934,  the  registrant  has duly  caused  this report to be signed on its
behalf by the undersigned, thereunto duly authorized.


                               INFORMEDICS, INC.


Date:  January 25, 1996            By: /s/ John Tortorici
      ---------------------        ----------------------------
                                    John Tortorici, President


Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed below by the following  persons on behalf of the  Registrant and
in the capacities and on the dates indicated.



Date:  January 25, 1996     By: /s/ John Tortorici
      ---------------------    --------------------------
                               John Tortorici, President,
                               Principal Executive Officer,
                               and Director


Date:   January 25, 1996    By: /s/ Dale E. Connor
       --------------------      --------------------------
                               Dale E. Conner, Vice President
                               & Chief Financial Officer

Date:   January 26, 1996    By: /s/ Richard D. Glaser
       ---------------------    ---------------------------
                               Richard D. Glaser, Ph.D., Director


Date:   January 25, 1996    By: /s/ Charles V. Dexter
       ---------------------    ---------------------------
                               Charles V. Dexter, Senior Vice
                               President, & Director



Date:   January 26, 1996    By: /s/ Ronald G. Witcosky
       --------------------     ---------------------------
                               Ronald G. Witcosky, Director


<PAGE>

                                                   EXHIBIT INDEX

Exhibit                                                                   Page

3(a)              Restated Articles of Incorporation, as amended (1)

3(b)              Restated Bylaws, as amended (7)

4                 Form of Indemnification Agreement--
                  Directorship and Officership Agreement (2)

10(a)*            Restated 1983 Employees' Stock Option Plan (3)

10(b)*            Restated 1988 Employees' Stock Option Plan, as amended (4)

10(c)             Lease with Beim & James Properties, as amended (5)

10(d)*            Incentive Compensation Plan (5)

10(e)             Amendments to Lease with Kruse Way Holdings, Inc. (formerly
                  Beim & James Properties) (8)

11                Computation of Earnings Per Share           

13                Portions of 1995 Annual Report to Shareholders, which are
                  incorporated by reference in this Form 10-KSB        

20                Definitive Proxy Statement for 1996 Annual Shareholder
                  Meeting (6)

23                Independent Auditors' Consent                             

27                Financial Data Schedule

* Management contract or compensatory plan or arrangement.

(1)  Incorporated  herein by reference from the Company's  annual report on Form
     10-K for the year ended October 31, 1993.

(2)  Incorporated  herein  by  reference  from the  Company's  definitive  proxy
     material  filed with the  Securities  and Exchange  Commission on April 28,
     1988.

(3)  Restated  1983  Employees'  stock  option  plan is  incorporated  herein by
     reference  from the  Company's  quarterly  report Form 10-Q for the quarter
     ended  April 30,  1988.  Amendment  to the Plan is  incorporated  herein by
     reference from the  registration  statement,  Form S-8 (Reg. No.  33-46474)
     filed with the Securities and Exchange Commission on March 19, 1992.

(4)  Incorporated  herein  by  reference  from the  Company's  definitive  proxy
     material filed with the  Securities and Exchange  Commission on February 8,
     1992.

(5)  Incorporated  herein by reference from the Company's  annual report on Form
     10-K for the year ended October 31, 1990.

(6)  To be filed with the  Securities  and Exchange  Commission  within 120 days
     after the end of the fiscal year covered by this Annual Report.

(7)  Incorporated  herein by reference  from the Company's  quarterly  report on
     Form 10-Q for the quarter ended April 30, 1993.

(8)  Incorporated  herein by reference from the Company's  annual report on Form
     10-KSB for the year ended October 31, 1994.